Darnitsa Launched 5 Medicinal Products in the 1st Quarter of 2021

In the 1st quarter of 2021, Darnitsa Pharmaceutical Company launched 5 medicinal products for the treatment of cardiac, neurological, gastroenterological and respiratory diseases.

In particular, in March, Darnitsa presented the medicinal product Memtek (active ingredient – memantine hydrochloride) for the treatment of dementia, which is manufactured for Darnitsa in the EU.

The company noted that the acceleration of the release of new medicines was made possible by the transition to electronic pharmaceutical document management, digitalization of clinical research processes and monitoring of the use of medicines.

More than half of the launches are implemented ahead of schedule, which for different products is from 1 to 3 months.

Darnitsa plans to launch 25 new medicinal products by the end of this year. Some launch products are the result of cooperation with European pharmaceutical companies. In total, during 2015-2020, Darnitsa launched 50 pharmaceutical brands, having invested about UAH 1.1 billion in the R&D.

Darnitsa Pharmaceutical Company was founded in 1930. Since 1998, it has been the leader in Ukraine in terms of production of medicinal products by volume. The strategic areas of the portfolio development include cardiology, mental health and pain management. The beneficiaries of the company are the Zagoriy family.